DLin-MC3-DMA
DC10800
Recommended because it shares a closely related research category or delivery context. Formulation and performance are product- and study-specific.
View product →| CAS No. | Not available |
| Chemical Name | AA-T3A-C12 |
| Synonyms | AAT3AC12， AA T3A C12 |
| SMILES | OC(CCCCCCCCCC)CN(CC(O)CCCCCCCCCC)CCCN(CCCNC(C1=CC=C(OC)C=C1)=O)CCCN(CC(O)CCCCCCCCCC)CC(O)CCCCCCCCCC |
| Formula | C65H126N4O6 |
| M.Wt | 1,059.72 |
| Purity | ELSD-HPLC>95% |
| Storage | Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light. |
| Shipping condition | Ships from Shanghai. Pure lipid is stable during ice-pack transport. |
| Publication | Han X, Gong N, Xue L, et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nature Communications. 2023;14:75. |
Literature-reported formulation composition
| Component | mol% | Role |
|---|---|---|
| AA-T3A-C12 | 50 | Ionizable lipid |
| DSPC | 10 | Helper phospholipid |
| Cholesterol | 38.5 | Sterol |
| C14-PEG2000 | 1.5 | PEG lipid |
| Reported total | 100 | Source values retained |
Formulation calculator unavailable. The reported four-component ratio is complete, but the exact chemical identity and average molecular weight of C14-PEG2000 (Avanti #880150) have not been reconciled. The formulation weight calculator and supporting-component bundle remain unavailable. Obtain and verify the complete composition and component molecular weights before planning component quantities.
Literature-reported performance for the cited formulation
Calculated from published source data82.31 ± 1.15%50 nM siGFP; 48 h; n=3 · With 30 micromolar haloperidol pretreatment: 49.80 ± 6.87% from raw values [44.66512323, 57.60886545322, 47.124865451]Main PDF p.3, Fig. 2d-e; Source Data 'Fig 2d'!C10:H10
Calculated from published source data65.48 ± 4.98%50 nM siHSP47; 48 h; n=3 · MC3/siHSP47 LNP mean 33.77% from raw values [29.6, 38.5, 33.2]Main PDF pp.5-6, Fig. 4e; Source Data 'Fig 4e'!D7:E9
Calculated from published source data65.2% knockdown versus PBS disease controlMale BALB/c mice, 6-8 weeks, CCl4 0.7 microliter/g intraperitoneally twice weekly for 4 weeks; LNP 5 micrograms siRNA/mouse (0.2 mg/kg) intravenously twice weekly during weeks 3-4; tissue collected 2 days after the last treatment. · PBS disease control and MC3/siHSP47 LNP; paper reports MC3 knockdown 31%.Calculated from mean normalized Western-blot values: PBS 18.3, AA-T3A-C12/siHSP47 6.3667; consistent with the paper-reported approximately 65%.Main PDF pp.6 and 8, Fig. 5b/f; pp.10-11, Methods; Source Data 'Fig 5f'!D5:G7
Calculated from published source data3.745 ± 0.898% collagen-positive areaSame therapeutic regimen; n=5 · PBS disease control raw [9.39, 7.67, 9.26, 8.18, 10.1]; MC3/siHSP47 LNP was less effective in the authors' analysis.Mean/sample SD of five AA-T3A-C12/siHSP47 animals. Derived reduction versus the PBS disease-control mean (8.92%) is 58.0%.Main PDF pp.7-8, Fig. 6a-b; Source Data 'Fig 6b'!D6:G10
Reported LNP particle properties
| Parameter | Reported result | Source |
|---|---|---|
| Size (DLS) | 65.6 ± 1.2 nm | Supplementary Table S1 |
| PDI | 0.018 | Supplementary Table S1 |
| Encapsulation efficiency | 87.4 ± 3.8% | Supplementary Table S1 |
| Zeta potential | −1.1 ± 1.5 mV | Supplementary Table S1 |
| Apparent pKa (TNS) | 5.72 | Main article, characterization |
Main PDF p.2, Fig. 1a; p.4, Characterization; pp.9-10, LNP formulation and characterization; SI p.27, Table S1
Additional reported findings
Predominant liver localization, with no significant difference in total liver accumulation versus MC3 (p=0.443). Confocal microscopy showed more AA-T3A-C12 signal colocalized with or near alpha-SMA-positive activated HSCs than MC3.
5 micrograms/mouse IV; fibrotic male BALB/c mice; organs at 1 h; n=3 · Main PDF p.6, Fig. 5a and p.8 caption; SI p.20, Fig. S20; Source Data 'Fig 5a'!B7:K12In fibrotic mice, AA-T3A-C12/siGFP LNP did not significantly increase ALT, AST or TBIL versus the PBS disease control; cytokines were not increased by LNP regimens and no histological damage was observed in heart, spleen, lung or kidney.
This is tolerability in a CCl4 injury model under one repeated-dose regimen, not a general toxicology package. · Main PDF pp.6-8, Fig. 6c-e; SI pp.23-24, Figs. S22-S23; Source Data 'Fig 6c'!B4:F9, 'Fig 6d'!B6:F11, 'Fig 6e'!B6:F11, 'Fig S22'!B3:M9Literature Data DisclaimerAll formulation parameters and performance values shown in this section are derived from the cited publication and are provided for reference only. These results were obtained using the specific materials, formulation process, cargo, dose, analytical method, model and administration route described in that study. Unless otherwise stated, the data were not generated or independently verified by DC Chemicals. DC Chemicals supplies the lipid compound only and does not guarantee that customers will reproduce the reported LNP properties or biological performance.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
The administration route shown above was used in the cited study and is not a clinical-use instruction or recommendation by DC Chemicals.
Cited literature for this formulation and performance datasetHan X, Gong N, Xue L, et al. Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis. Nature Communications. 2023;14:75. DOI: 10.1038/s41467-022-35637-z
Composition, particle properties and study methods come from the main article and SI. Results labelled calculated were computed from the cited published source-data cells; their assay conditions and comparators are retained. No product-specific human efficacy is established.
Composition, particle properties and study methods come from the main article and SI. Results labelled calculated were computed from the cited published source-data cells; their assay conditions and comparators are retained. No product-specific human efficacy is established.